[go: up one dir, main page]

PT1003534E - Reovirus para o tratamento de neoplasia - Google Patents

Reovirus para o tratamento de neoplasia

Info

Publication number
PT1003534E
PT1003534E PT98940002T PT98940002T PT1003534E PT 1003534 E PT1003534 E PT 1003534E PT 98940002 T PT98940002 T PT 98940002T PT 98940002 T PT98940002 T PT 98940002T PT 1003534 E PT1003534 E PT 1003534E
Authority
PT
Portugal
Prior art keywords
reovirus
neoplasia
treatment
neoplasm
pkr
Prior art date
Application number
PT98940002T
Other languages
English (en)
Inventor
Patrick W K Lee
James Strong
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of PT1003534E publication Critical patent/PT1003534E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT98940002T 1997-08-13 1998-08-12 Reovirus para o tratamento de neoplasia PT1003534E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/911,383 US6110461A (en) 1997-08-13 1997-08-13 Reovirus for the treatment of neoplasia

Publications (1)

Publication Number Publication Date
PT1003534E true PT1003534E (pt) 2002-08-30

Family

ID=25430159

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98940002T PT1003534E (pt) 1997-08-13 1998-08-12 Reovirus para o tratamento de neoplasia

Country Status (15)

Country Link
US (9) US6110461A (pt)
EP (3) EP1213023A1 (pt)
JP (1) JP4291884B2 (pt)
AT (1) ATE213948T1 (pt)
AU (1) AU731810B2 (pt)
CA (1) CA2283280C (pt)
DE (2) DE1003534T1 (pt)
DK (1) DK1003534T3 (pt)
ES (1) ES2157870T3 (pt)
GR (1) GR20010300030T1 (pt)
HK (1) HK1028340A1 (pt)
IL (1) IL131598A (pt)
NZ (1) NZ337493A (pt)
PT (1) PT1003534E (pt)
WO (1) WO1999008692A1 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
CA2720361A1 (en) 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020147996A1 (en) * 2000-07-07 2002-10-10 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20020156039A1 (en) * 2000-07-07 2002-10-24 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
JP4146725B2 (ja) 2000-11-09 2008-09-10 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性障害の処置のための方法
EP1335737A2 (en) * 2000-11-20 2003-08-20 Oncolytics Biotech, Inc. Method for optimally delivering virus to a solid tumor mass
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
CA2430495A1 (en) * 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2002074940A1 (en) 2001-03-16 2002-09-26 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
WO2003011230A2 (en) * 2001-08-03 2003-02-13 Board Of Regents, The University Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (en) * 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
US7319001B2 (en) 2002-03-09 2008-01-15 Neurogenex Co., Ltd. High throughput system for producing recombinant viruses using site-specific recombination
ATE427990T1 (de) 2002-04-30 2009-04-15 Oncolytics Biotech Inc Verbesserte reinigungsmethode fur viren
SI1505992T1 (sl) * 2002-05-09 2009-02-28 Oncolytics Biotech Inc Postopek za zmanjšanje bolečine z uporabo onkolitičnih virusov
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
AU2003238008A1 (en) * 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004060365A1 (en) * 2002-12-30 2004-07-22 American Health Foundation Compositions and methods for treating lung cancer
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
NZ542902A (en) 2003-03-27 2007-06-29 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
SG149069A1 (en) * 2003-09-26 2009-01-29 Novartis Ag Seneca valley virus based compositions and methods for treating disease
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (en) * 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
DK1984007T3 (en) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
MX2009009598A (es) * 2007-03-12 2009-09-21 Oncolytics Biotech Inc Reovirus que tienen secuencias modificadas.
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
CN102065873A (zh) * 2008-05-27 2011-05-18 昂科利蒂克斯生物科技公司 在溶瘤呼肠孤病毒治疗中消除促炎细胞因子的产生
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
JP5944901B2 (ja) 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
WO2013163724A1 (en) * 2012-04-30 2013-11-07 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2014204275A1 (ko) * 2013-06-21 2014-12-24 한국생명공학연구원 리오바이러스를 유효성분으로 함유하는 혈관신생 억제용 조성물
CA2930629A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
KR20230012484A (ko) * 2020-05-20 2023-01-26 바이로큐어 주식회사 암 예방 또는 치료용 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
PT70556A (en) * 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
US4490358A (en) 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) * 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
CA2045129A1 (en) * 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
WO1990011765A1 (en) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
PT931830E (pt) * 1993-02-16 2001-08-30 Onyx Pharma Inc Virus citopaticos para terapia e profilaxia de neoplasia
US5525342A (en) * 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
EP1032269B1 (en) 1997-10-09 2007-08-29 Wellstat Biologics Corporation Treatment of neoplasms with interferon-sensitive, clonal viruses
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
JP4146725B2 (ja) * 2000-11-09 2008-09-10 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性障害の処置のための方法
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
EP1505993B1 (en) * 2002-05-10 2012-04-25 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
CN101304761A (zh) * 2005-08-31 2008-11-12 昂科利蒂克斯生物科技公司 用溶瘤病毒和免疫刺激剂治疗以增强体内免疫系统对肿瘤的识别
MX2009009598A (es) * 2007-03-12 2009-09-21 Oncolytics Biotech Inc Reovirus que tienen secuencias modificadas.

Also Published As

Publication number Publication date
ES2157870T1 (es) 2001-09-01
ES2157870T3 (es) 2002-10-16
US20050123513A1 (en) 2005-06-09
DE69804106D1 (de) 2002-04-11
US20040265271A1 (en) 2004-12-30
EP1003534B1 (en) 2002-03-06
DE1003534T1 (de) 2001-08-23
ATE213948T1 (de) 2002-03-15
JP2002511886A (ja) 2002-04-16
GR20010300030T1 (en) 2001-08-31
HK1028340A1 (en) 2001-02-16
US20090110665A1 (en) 2009-04-30
IL131598A0 (en) 2001-01-28
WO1999008692A1 (en) 1999-02-25
NZ337493A (en) 2000-12-22
EP1433483A1 (en) 2004-06-30
AU8847198A (en) 1999-03-08
US7300650B2 (en) 2007-11-27
US6576234B2 (en) 2003-06-10
AU731810C (en) 1999-03-08
US20020187125A1 (en) 2002-12-12
US20010048920A1 (en) 2001-12-06
DE69804106T2 (de) 2002-08-14
CA2283280C (en) 2005-10-18
EP1213023A1 (en) 2002-06-12
US6110461A (en) 2000-08-29
US6344195B1 (en) 2002-02-05
US20090098089A1 (en) 2009-04-16
CA2283280A1 (en) 1999-02-25
DK1003534T3 (da) 2002-05-21
JP4291884B2 (ja) 2009-07-08
AU731810B2 (en) 2001-04-05
US6261555B1 (en) 2001-07-17
US7476382B2 (en) 2009-01-13
IL131598A (en) 2005-03-20
EP1003534A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
PT1003534E (pt) Reovirus para o tratamento de neoplasia
ES2539272T3 (es) Uso terapéutico de precursor de óxido nítrico
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
ES2035384T3 (es) Procedimiento para la esterilizacion de sangre, plasma, derivados de la sangre y del plasma, suspensiones celulares o similares.
ES2040137T3 (es) Agente para la tincion del pelo y su empleo.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
CA2008078A1 (en) Use of Dimethylpolysiloxane for the Treatment of Disorders of the Gastrointestinal Tract
ES2134184T3 (es) Empleo de etisterona para el tratamiento topico del acne o de la alopecia androgenetica.
FI852730L (fi) (pyrrol-1-yl) -fenyl-dihydropyridazinoner, deras framstaellning och anvaendning.
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
ES2191206T3 (es) Nueva utilizacion de la creatina.
PT813870E (pt) Utilizacao da darifenacina para aumentar funcoes cognitivas
ES538403A0 (es) Procedimiento para la obtencion de antipodas opticos del (+7-1,7-difenil-3-metilaza-7-ciano-8-metil-nonano
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
MX9201258A (es) Compuestos para el tratamiento del cancer y procedimiento para su preparacion.
UY27060A1 (es) Composición vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
TR200001075T2 (tr) Tiamfenikol ve diklofenak içeren bileşimler.
HK88396A (en) 24r-scymnol and preparation and use thereof
SE8802040D0 (sv) New use
PT661058E (pt) Utilizacao de antagonistas da bradiquinina para o tratamento de doencas virais
BR9711960A (pt) Verapamil como um medicamento para o tratamento de angina
SE9602262D0 (sv) New use of derivatives of cystine